Last Updated: 2026-03-17 PT
This page ranks research gaps in neurodegenerative disease research by priority and impact. Identifying and addressing these gaps is essential for advancing our understanding of disease mechanisms and developing effective therapies.
| Rank | Gap Area | Priority | Impact |
|---|---|---|---|
| 1 | Mechanism Validation | High | Critical |
| 2 | Biomarker Development | High | Critical |
| 3 | Treatment Efficacy | High | Critical |
| 4 | Disease Prevention | Medium | High |
| 5 | Early Detection | Medium | High |
| 6 | Genetic Risk Factors | Medium | High |
| 7 | Disease Models | Medium | Medium |
| 8 | Clinical Trial Design | Medium | Medium |
| Rank | Gap | Unanswered Questions |
|---|---|---|
| 1 | Disease Initiation | What triggers initial protein aggregation? |
| 2 | Progression Mechanisms | How does pathology spread between neurons? |
| 3 | Treatment Resistance | Why do treatments fail in advanced disease? |
| 4 | Biomarkers | Which markers predict disease progression? |
| 5 | Genetic Risk | What modifies risk in gene carriers? |
| 6 | Cellular Vulnerability | Why are certain neurons selectively vulnerable? |
| 7 | Protein Aggregation | What determines toxic versus benign aggregates? |
| 8 | Neuroinflammation | What is the primary versus secondary role? |
Why it matters: Understanding the precise molecular mechanisms driving neurodegeneration is essential for target validation and drug development.
Key questions:
Current status: Multiple hypotheses exist (amyloid cascade, alpha-synuclein propagation, mitochondrial dysfunction) but none fully explain disease progression[1][2][3].
Why it matters: Biomarkers enable early diagnosis, patient stratification, and treatment monitoring.
Key questions:
Current status: Amyloid and tau CSF biomarkers are established for AD[1:1]; fluid biomarkers for PD are in development[2:1].
Why it matters: Current treatments only manage symptoms; disease-modifying therapies are urgently needed.
Key questions:
Current status: Anti-amyloid antibodies show modest benefits in early AD[4]; neuroprotective strategies remain elusive[3:1].
Why it matters: Prevention strategies could significantly reduce disease burden if modifiable risk factors are identified.
Key questions:
Current status: Several modifiable risk factors identified (cardiovascular, education, physical activity)[5]; trials of prevention strategies ongoing[6].
Why it matters: Neurodegeneration begins years before symptoms; early detection enables early treatment.
Key questions:
Current status: Research criteria for preclinical AD established[1:2]; similar frameworks developing for PD[2:2].
Several gaps span multiple diseases:
Protein Aggregation Mechanisms: Understanding how misfolded proteins form toxic aggregates and spread between neurons applies to AD (amyloid, tau), PD (alpha-synuclein), and ALS (TDP-43)[2:3][3:2].
Neuroinflammation Role: Determining whether gliosis is a cause or consequence of neurodegeneration has therapeutic implications across diseases[3:3].
Cellular Energy Metabolism: Mitochondrial dysfunction appears in multiple neurodegenerative conditions; targeting energy metabolism may have broad benefits[3:4].
Selective Neuronal Vulnerability: Understanding why specific neuron populations degenerate could enable targeted neuroprotection[2:4].
Jack et al. Alzheimer's disease: Nat Rev Dis Primers (2018). 2018. ↩︎ ↩︎ ↩︎
[Kalia & Lang, Parkinson's disease: Lancet (2015)](https://doi.org/10.1016/S0140-6736(14). 2015. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Hardy & Mummery, Neurodegeneration research gaps: Nat Rev Neurosci (2019). 2019. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Masters et al. [Alzheimer's disease: Lancet Neurology (2024)](https://doi.org/10.1016/S1474-4422(24). 2024. ↩︎
2023-2024 Alzheimer's Disease Research Summit Recommendations. 2023. ↩︎